Community Member Nominations are Now Being Accepted for the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents with HIV

The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for a community representative to serve a four-year term beginning September 2024 with potential for reappointment for one additional term. The Panel welcomes diversified representation in the community membership reflecting the demographics of the current HIV epidemic in the US. The community member may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituency they represent. The candidate shall have knowledge of, and involvement in, issues related to management of adults and adolescents with HIV, as evidenced by experience in HIV treatment education/advocacy or clinical/public policy initiatives related to HIV treatment.

The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is comprised of over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the US. The Panel meets monthly via videoconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy and to revise theGuidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.

Panel members are not compensated for their time commitment. Panel members are required to report any relationship with companies involved with antiretroviral agents or diagnostic tests relevant to antiretroviral treatment. Panel members are not allowed to be part of a pharmaceutical companys speaker bureau.

The nomination should include a resume and a letter of nomination or a letter of interest with specific reference as to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Alice Pau, Pharm.D. (apau@niaid.nih.gov) or Marylu Schaffhauser (marylu.schaffhauser@nih.gov) electronically by May 24, 2024.